FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

While many people are familiar with mammograms and smear tests, prostate screening is talked about far less. To shed light on this important subject ahead of Prostate Cancer Awareness Month in March, ...

A stage 4 prostate cancer survivor shares his story of positivity and gratitude. After doing some yard landscaping, I began to have some rather severe back pain and muscle spasms. My first thought was ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

The addition of hormone therapy to radiotherapy improves overall survival in men with high-risk prostate cancer, over ...

A group of doctors who specialize in cancer have detailed four subtle symptoms of the disease that people often overlook. The American Cancer Society predicts 2.1 million people in the US will be ...

Researchers at King's College London have discovered that an immune protein best known for protecting the body against ...

PYLARIFY TruVu™ (piflufolastat F 18) injection (also known as 18F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and ...

Jersey Shore alum Nicole "Snooki" Polizzi shared that she was diagnosed with stage one cervical cancer after years of painful ...

So for the listeners out there, maybe they're seeing some prostate cancer, they're seeing a lot, they're trying to think about factors to look for and who those patients we should be looking for. Is ...

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...